Search - tctmd.com

Displaying 61 - 80 of 88

Sort: Relevancy | Date

News Daily News

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

L.A. McKeown

August 24, 2016

News Daily News

Mejor Supervivencia y Ausencia de ‘Tendencia de Riesgo’ para TAVR vs Cirugía en Pacientes de Menor Riesgo

L.A. McKeown

August 24, 2016

Presentation TVT 2016

Highlights From PARTNER 2A in Intermediate-Risk Patients

Presenter: Michael J. Mack

June 16, 2016

News Daily News

大规模 Meta 分析显示，TAVR 与手术 30 天和 1 年死亡率相当

Michael O'Riordan

June 07, 2016

News Daily News

Según un Gran Meta Análisis Parecida Mortalidad al cabo de 30 Días y 1 Año con TAVR Versus Cirugía

Michael O'Riordan

June 07, 2016

News Daily News

Equivalent Mortality at 30 Days and 1 Year With TAVR vs Surgery, Says Large Meta-analysis

Michael O'Riordan

June 07, 2016

News Opinion Editor's Corner ACC 2016

Hot or Not, This Year’s Trials Offer Food for Thought: My Takeaways From ACC 2016

Shelley Wood

April 13, 2016

News Conference News ACC 2016

Sapien 3 Superior to Surgery Among Intermediate-Risk Patients in Observational Trial

Yael L. Maxwell

April 03, 2016

News Conference News ACC 2016

TAVR With Sapien XT Noninferior to Surgery in Intermediate-Risk Patients, With a Win for Transfemoral

Shelley Wood

April 02, 2016

News Daily News

La Valvuloplastia Mejora el Pronóstico a Corto Plazo de Pacientes con Estenosis Aórtica Tratada Médicamente

February 19, 2015

News Daily News

Los Datos del Registro PARTNER Documentan los Avances en TAVR Transfemorales

L.A. McKeown

December 04, 2014

Presentation TCT 2014

Updates from PARTNER 2A and Sapien 3 in Intermediate-Risk Patients

Presenter: Martin B. Leon, Neil E. Moat, Ariel Finkelstein, Vinod H. Thourani

September 13, 2014

News Daily News

CoreValve Reduce la Mortalidad al cabo de 1 Año en Pacientes de Riesgo Quirúrgico Extremo

March 20, 2014

Presentation TCT 2013

Lessons Learned from PARTNER 2A and SURTAVI: Device Specificity, Trial Design, Endpoints, and Future Low-risk Studies

Presenter: Jodi Akin

October 30, 2013

Presentation TCT 2013

Status Update on the Randomized Moderate Risk AS Trials: PARTNER 2A

Presenter: Martin Leon

October 27, 2013

News Daily News

Meta Análisis: A las Mujeres les Va Mejor que a los Hombres tras una TAVR a pesar de tener Más Complicaciones

Yael L. Maxwell

September 27, 2013

Advertisement

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

Mejor Supervivencia y Ausencia de ‘Tendencia de Riesgo’ para TAVR vs Cirugía en Pacientes de Menor Riesgo

Highlights From PARTNER 2A in Intermediate-Risk Patients

大规模 Meta 分析显示，TAVR 与手术 30 天和 1 年死亡率相当

Según un Gran Meta Análisis Parecida Mortalidad al cabo de 30 Días y 1 Año con TAVR Versus Cirugía

Equivalent Mortality at 30 Days and 1 Year With TAVR vs Surgery, Says Large Meta-analysis

Hot or Not, This Year’s Trials Offer Food for Thought: My Takeaways From ACC 2016

Sapien 3 Superior to Surgery Among Intermediate-Risk Patients in Observational Trial

TAVR With Sapien XT Noninferior to Surgery in Intermediate-Risk Patients, With a Win for Transfemoral

La Valvuloplastia Mejora el Pronóstico a Corto Plazo de Pacientes con Estenosis Aórtica Tratada Médicamente

Los Datos del Registro PARTNER Documentan los Avances en TAVR Transfemorales

Updates from PARTNER 2A and Sapien 3 in Intermediate-Risk Patients

CoreValve Reduce la Mortalidad al cabo de 1 Año en Pacientes de Riesgo Quirúrgico Extremo

Lessons Learned from PARTNER 2A and SURTAVI: Device Specificity, Trial Design, Endpoints, and Future Low-risk Studies

Status Update on the Randomized Moderate Risk AS Trials: PARTNER 2A

Meta Análisis: A las Mujeres les Va Mejor que a los Hombres tras una TAVR a pesar de tener Más Complicaciones

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content